July 11, 2025 07:00 AM EDT

Century Therapeutics lays off half of its staff, CFO departs as it narrows priorities

Ayisha Sharma

News Reporter

Cell therapy maker Century Therapeutics is cutting its workforce by around half in an effort to “right-size” the business as it homes in on therapeutic …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Century Therapeutics lays off half of its staff, CFO departs as it narrows priorities

Ayisha Sharma

News Reporter

Sign up to read this article for free.

FDA hands Capricor a CRL for its Duchenne cell therapy

Sally Susman waves goodbye to Pfizer; Xaira's new president and COO

Updated: FDA publishes repository of 200+ drug rejection letters, promising more in the future

Biotech’s Q2 numbers paint a picture of the good, the bad and the ugly

As researchers come together for HIV conference, few biotechs can stay the course

Uncovering the Potential of Targeting the CD38 Pathway for Immune-Mediated Diseases

Cen­tu­ry Ther­a­peu­tics lays off half of its staff, CFO de­parts as it nar­rows pri­or­i­ties

Ayisha Sharma

News Reporter

Sign up to read this article for free.

FDA hands Capri­cor a CRL for its Duchenne cell ther­a­py

Sal­ly Sus­man waves good­bye to Pfiz­er; Xaira's new pres­i­dent and COO

Up­dat­ed: FDA pub­lish­es repos­i­to­ry of 200+ drug re­jec­tion let­ters, promis­ing more in the fu­ture

Biotech’s Q2 num­bers paint a pic­ture of the good, the bad and the ug­ly

As re­searchers come to­geth­er for HIV con­fer­ence, few biotechs can stay the course

Un­cov­er­ing the Po­ten­tial of Tar­get­ing the CD38 Path­way for Im­mune-Me­di­at­ed Dis­eases

Century Therapeutics lays off half of its staff, CFO departs as it narrows priorities

FDA hands Capricor a CRL for its Duchenne cell therapy

Sally Susman waves goodbye to Pfizer; Xaira's new president and COO

Updated: FDA publishes repository of 200+ drug rejection letters, promising more in the future

Biotech’s Q2 numbers paint a picture of the good, the bad and the ugly

As researchers come together for HIV conference, few biotechs can stay the course

Uncovering the Potential of Targeting the CD38 Pathway for Immune-Mediated Diseases